Trevi Therapeutics to present Phase 2b CORAL nalbuphine ER quality-of-life data in IPF cough at ERS 2026

PUBT · 1d ago
Trevi Therapeutics to present Phase 2b CORAL nalbuphine ER quality-of-life data in IPF cough at ERS 2026
  • Trevi Therapeutics set two ERS Congress 2026 presentations for September 7 in Barcelona on nalbuphine ER for chronic cough.
  • Results have not been presented yet; the company will disclose quality-of-life findings from Phase 2b CORAL in IPF-related chronic cough.
  • A second presentation will cover quality-of-life outcomes from the Phase 2a RIVER study in refractory chronic cough.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trevi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608260730PRIMZONEFULLFEED9815917) on August 26, 2026, and is solely responsible for the information contained therein.